In the treatment of trichotillomania, is fluvoxamine or nortriptyline the preferred medication?

Fluvoxamine Over Nortriptyline for Trichotillomania

Neither fluvoxamine nor nortriptyline should be used as first-line pharmacotherapy for trichotillomania—both lack robust evidence of efficacy, but if forced to choose between these two agents, fluvoxamine is the safer option due to nortriptyline's significant psychomotor impairment and anticholinergic burden.

Evidence-Based Treatment Hierarchy

The current evidence for trichotillomania treatment demonstrates:

First-Line Interventions (Strongest Evidence)

• Behavioral therapy with habit reversal remains the gold standard with the largest effect sizes (ES = -1.14) 1, 2
• N-acetylcysteine (NAC) shows the most consistent pharmacological benefit with favorable safety profile 3, 2, 4, 5
• Acceptance and Commitment Therapy-enhanced habit reversal demonstrates strong replication 2

Second-Line Pharmacological Options

• Clomipramine (not nortriptyline) shows modest evidence with ES = -0.68, superior to SSRIs but inferior to behavioral interventions 1, 3
• Olanzapine has preliminary positive data from small trials 3

Why Neither Drug is Optimal

Fluvoxamine's Limited Evidence

• Only one open-label trial (n=21) showed minimal improvement in hair-pulling measures 6
• The study found improvement only in "distress, duration, control, and resistance"—not actual hair-pulling behavior 6
• No placebo-controlled trials specifically for trichotillomania
• Meta-analyses confirm SSRIs show no efficacy (ES = 0.02) for trichotillomania 1
• A 2013 Cochrane review found "none of the three studies of SSRIs demonstrated strong evidence of a treatment effect" 3

Nortriptyline's Significant Drawbacks

• Zero published evidence for efficacy in trichotillomania
• Causes significant psychomotor impairment across all objective and subjective measures 7
• Higher anticholinergic and cardiovascular adverse event profile compared to SSRIs 8
• Dry mouth, sedation, and cognitive impairment limit tolerability 7

Clinical Decision Algorithm

If you must prescribe one of these medications:

1. Choose fluvoxamine (50-300 mg/day) over nortriptyline based on:

   • At least minimal published data in trichotillomania 6
   • Better tolerability profile with fewer psychomotor effects 7
   • Lower cardiovascular and anticholinergic burden 8

2. Monitor for fluvoxamine-specific concerns:

   • Significant drug interactions via CYP1A2 inhibition (avoid with theophylline, warfarin, diazepam) 9
   • Nausea (>10% of patients) 9, 8
   • Gradual taper required to avoid discontinuation syndrome 9

3. Set realistic expectations:

   • Even if improvement occurs, it will likely be in distress/anxiety rather than hair-pulling behavior 6
   • Consider this a temporizing measure while arranging habit reversal therapy

Strongly Recommended Alternative Approach

Rather than using either medication, the evidence-based strategy is:

1. First-line: Habit reversal therapy (HRT) with or without NAC 1200-2400 mg/day 1, 2, 4, 5
2. If SSRIs are poorly tolerated: Consider bupropion combined with mindfulness-based behavioral therapy 10
3. Refractory cases: Clomipramine (not nortriptyline) or olanzapine with behavioral therapy 3, 2

Critical Pitfalls to Avoid

• Do not assume trichotillomania responds like OCD to serotonergic agents—the evidence clearly shows SSRIs lack efficacy for hair-pulling despite theoretical similarities 1, 3
• Do not use nortriptyline simply because it's a tricyclic antidepressant—clomipramine's serotonergic properties are what provide benefit, not the tricyclic structure itself
• Do not prescribe fluvoxamine without checking drug interactions—particularly dangerous with warfarin (98% increase in plasma levels), theophylline (3-fold decreased clearance), and benzodiazepines 9

The most recent comprehensive meta-analysis (2026) emphasizes that pharmacotherapy without habit reversal shows minimal benefit, and when SSRIs are used, they should be combined with behavioral interventions 2, 5.